BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6236-6241

  Choi, Hye Eun ^a   Yoo, Min Sang ^a   Choi, Jung Hye ^a   Lee, Jae Yeol ^a   Kim, Je Hak ^b   Kim, Ji Han ^b   Lee, Joon Kwang ^b   Kim, Gyu Il ^b   Park, Yong ^b   Chi, Yong Ha ^b   Paik, Soo Heui ^b   Lee, Joo Han ^b   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Boryung Pharm Co Ltd   (South Korea)

Author keywords

Anti angiogenesis; HUVECs; Nicotinamide; VEGF; VEGR2

Indexed keywords

2 (1 BENZYLPIPERIDIN 4 YL) AMINO N (3 CHLOROPHENYL)NICOTINAMIDE; BRN 103; BRN 218; BRN 228; BRN 229; BRN 279; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NICOTINAMIDE DERIVATIVE; PROTEIN KINASE B; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING;

EID: 80054788763     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.022     Document Type: Article

References (26)

1. Folkman, J. Nat. Med. 1995, 1, 27.
2. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. Nat. Rev. Mol. Cell Biol. 2006, 7, 359.
3. Huang, D.; Ding, Y.; Li, Y.; Luo, W. M.; Zhang, Z. F.; Snider, J.; Vandenbeldt, K.; Qian, C. N.; Teh, B. T. Cancer Res. 2010, 70, 1053.
4. Abrams, T. J.; Lee, L. B.; Murray, L. J.; Pryer, N. K.; Cherrington, J. M. Mol. Cancer Ther. 2003, 2, 471.
5. Abrams, T. J.; Murray, L. J.; Pesenti, E.; Holway, V. W.; Colombo, T.; Lee, L. B.; Cherrington, J. M.; Pryer, N. K. Mol. Cancer Ther. 2003, 2, 1011.
6. Mena, A. C.; Pulido, E. G.; Guillen-Ponce, C. Anticancer. Drugs 2010, 21, S3-S11.
7. Boehm, S.; Rothermundt, C.; Hess, D.; Joerger, M. Gerontology 2010, 56, 303.
8. Brunelleschi, S.; Penengo, L.; Santoro, M. M.; Gaudino, G. Curr. Pharm. Des. 2002, 8, 1959.
9. Ferrara, N.; Gerber, H. P.; LeCouter, J. Nat. Med. 2003, 9, 669.
10. Zhang, R.; Xu, Y.; Ekman, N.; Wu, Z.; Wu, J.; Alitalo, K.; Min, W. J. Biol. Chem. 2003, 278, 51267.
11. Carmeliet, P. Nature 2005, 438, 932.
12. Redmond, E. M.; Cahill, P. A.; Hirsch, M.; Wang, Y. N.; Sitzmann, J. V.; Okada, S. S. Thromb. Haemost. 1999, 81, 293.
13. Denker, S. P.; Barber, D. L. J. Cell Biol. 2002, 159, 1087.
14. Lim, H. J.; Lee, S.; Park, J. H.; Lee, K. S.; Choi, H. E.; Chung, K. S.; Lee, H. H.; Park, H. Y. Atherosclerosis 2009, 202, 446. Cellular proliferation was determined by BrdU incorporation assay using a commercial ELISA ki according to the manufacturer's instructions (Roche, Basel, Switzerland). Briefly, BRN-103, Sunitinib or VEGF treated cells were incubated with Brd specific monoclonal antibody. After addition of peroxidase conjugated secondary antibody, substrate and stop solution were added. The amount of BrdU incorporated was determined by measuring the absorbance at 450 nm.
15. Patan, S. Cancer Treat. Res. 2004, 117, 3.
16. Pang, X.; Yi, Z.; Zhang, X.; Sung, B.; Qu, W.; Lian, X.; Aggarwal, B. B.; Liu, M. Cancer Res 2009, 69, 5893. HUVECs were pretreated with indicated concentrations of BRN-103 or Sunitinib for 1 h and then seeded onto the Matrigel layer in 24-well plates at a density of 4-7 × 104 cells. EBM was with or without 10 ng/ml VEGF. After incubation for 6 h, tubular structure of endothelial cells was photographed using an inverted microscope (Olympus; magnification, × 100).
17. Pyun, B. J.; Choi, S.; Lee, Y.; Kim, T. W.; Min, J. K.; Kim, Y.; Kim, B. D.; Kim, J. H.; Kim, T. Y.; Kim, Y. M.; Kwon, Y. G. Cancer Res 2008, 68, 227. Mouse aortas isolated from Sprague-Dawley rats (NIH) were cleaned of periadventitial fat and cut into rings at 1-1.5 mm in circumference. The aortic rings were randomized into Matrigel-coated wells and sealed with a 100 μl overlay of Matrigel. VEGF, with or without indicated concentrations of BRN-103 or Sunitinib, was added to the wells. As a control, medium alone was assayed. After 7 day, we fixed the microvessel sprouting and photographed it using an Olympus inverted microscope (Olympus; magnification, × 100).
18. Masson-Gadais, B.; Houle, F.; Laferriere, J.; Huot, J. Cell Stress Chaperones 2003, 8, 37.
19. Shibuya, M.; Claesson-Welsh, L. Exp. Cell Res. 2006, 312, 549.
20. Brekken, R. A.; Overholser, J. P.; Stastny, V. A.; Waltenberger, J.; Minna, J. D.; Thorpe, P. E. Cancer Res. 2000, 60, 5117.
21. Murphy, D. A.; Makonnen, S.; Lassoued, W.; Feldman, M. D.; Carter, C.; Lee, W. M. Am. J. Pathol. 2006, 169, 1875.
22. Somanath, P. R.; Razorenova, O. V.; Chen, J.; Byzova, T. V. Cell Cycle 2006, 5, 512.
23. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Nature 1999, 399, 601.
24. Manning, B. D.; Cantley, L. C. Cell 2007, 129, 1261.
25. Huang, D.; Ding, Y.; Luo, W. M.; Bender, S.; Qian, C. N.; Kort, E.; Zhang, Z. F.; VandenBeldt, K.; Duesbery, N. S.; Resau, J. H.; Teh, B. T. Cancer Res. 2008, 68, 81.
26. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Cancer Res. 2006, 66, 11851.